Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- (-) Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- (-) Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- (-) Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- (-) Value-Based Contracts
- (-) Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 36 Results
Value-Based Agreements May Be More Prevalent Than Assumed
As the US health care system continues to transition from volume to value, NPC/Duke-Margolis research shows that value-based agreements between payers and biopharmaceutical manufacturers may be more…
NPC in Specialty Pharmacy Times: Health Care Economic Information and Its Impact on Value-Based Contracts
In his latest column in Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explains how expanding HCEI for sophisticated audiences like payers and population health…
NPC in STAT: Paying for Curative Therapies: Our Challenges in Addressing Medicine’s Solutions
In a commentary published in STAT, National Pharmaceutical Council Executive Vice President and Chief Science Officer Robert Dubois, MD, PhD, outlines some creative thinking behind how we could…
Are Payers Ready to Address the Financial Challenges Associated with Gene Therapy?
NPC and the Analysis Group conducted market research to explore payer views of the potential roles that existing and new alternative payment approaches could play in managing the financial risk and…
Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value
This white paper highlights the challenges biopharmaceutical manufacturers and payers face when developing value-based contracts.
NPC in Chain Drug Review: Pharmacy Outlook 2018
NPC President Dan Leonard explores value- and outcomes-based contracts, innovative benefit design, value assessment frameworks and more in his latest commentary for Chain Drug Review.
Opportunities and Challenges With Value-Based Contracting
In his commentary for the American Journal of Pharmacy Benefits, NPC President Dan Leonard explores the challenges and opportunities in implementing value-based contracts.
AMCP Partnership Forum on Value in Oncology Proceedings Published in JMCP
The Journal of Managed Care & Specialty Pharmacy this week published the proceedings from the Academy of Managed Care Pharmacy partnership forum, “Driving Value and Outcomes in Oncology,” which…
A Dynamic Approach to Consumer Cost-Sharing for Prescription Drugs
The level of consumer cost-sharing for higher cost medication should be aligned with the clinical value – not solely the price – when lower cost alternatives do not produce the desired patient…
Designing Successful Bundled Payment Initiatives
The National Pharmaceutical Council led a study that identified three principles intended to maximize the positive aspects and minimize the negative consequences of bundled payments.
Webinar: 2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making
Dan Leonard, MA, Kimberly Westrich, Joe Selby, MD, MPH, Lisa Simpson, MB, BCh, FAAP
Private Sector Risk-Sharing Agreements in the US: Trends, Barriers and Prospects
A peer-reviewed study found that there are limited risk-sharing agreements (RSAs) between health care payers and pharmaceutical manufacturers in the United States, but interest in the agreements…
Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design
Value-based insurance design (V-BID) is a key tactic payers and purchasers can use to promote access to high-value specialty medications.
Health Plan Capabilities to Support Value Based Benefit Design
This guide around health plan capabilities to support Value Based Benefit Design is meant to assist employers in understanding how to more effectively work with their health plans to implement…